Site icon Market Globalist

Is There A Reason Why IMNPQ Stock Closed The Last Session 101% Higher?

AMD Stock

AMD Stock

In the past session, Immune Pharmaceuticals Inc (OTC: IMNPQ) stock closed up 101.30% at $0.099 on OTCPink. In the session, the IMNPQ stock price ranged between $0.08 and $0.1478, with 49,757,016 shares changing hands. Recent acquisition offers could be the reason lifting the IMNPQ stock, but there is no news that could drive the stock higher right now.

Who made the acquisition offer?

Immune Pharmaceuticals develops and/or manufactures pharmaceutical agents that tackle immunologic and inflammatory diseases. IMNPQ’s lead pipeline candidate is bertilimumab, an antibody that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is currently testing in Phase II clinical trials.

Read More

In addition to the development of NanoCyclo, IMNPQ is also testing its use in atopic dermatitis and psoriasis in late stage preclinical testing. Furthermore, AmiKet and AmiKet Nano, which combine amitriptyline and ketamine for treating diabetic peripheral neuropathy, are also included in IMNPQ’s portfolio of pain products.

An unconditional offer has recently been extended to Immune Pharmaceuticals to take control of the publicly traded company.

Steps involved in the acquisition offer?

Court and SEC approval are required for the offer to acquire the Immune Pharmaceuticals (IMNPQ). The acquisition process to takeover IMNPQ will begin sometime in the near future. United General intends to apply to the SEC as soon as practicable to acquire IMNPQ.

Exit mobile version